IMDZ CC addendum: The company did not disclose—and no one on the CC asked—whether patients in the placebo arm will be allowed to receive CMB305 after disease progression. I presume that the answer is no.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”